Phosphodiesterase III inhibitor, augmenting cerebral blood flow by a direct vasodilator effect on cerebral arteries

Novel Bruton's tyrosine kinase inhibitor, suppressing B cell and monocyte activation and ameliorates arthritis in a mouse model

Novel specific agonist of odorant receptor 895 (Olfr895)

Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt

Natural inhibitor of the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site, reducing the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes, ameliorating pressure overload-induced cardiac hypertrophy

Dopamine antagonist as an atypical antipsychotic

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Novel orally bioavailable potent JAK-1 inhibitor

Novel Bax activator, having greatest effect enhancing the pro-apoptotic activity of Bax with EC50 values of ∼0.1 μM and ∼0.9 μM, respectively, inducing cell death by a Bax/Bak-dependent mechanism

Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo

Novel HSF1 inhibitor for target-based cancer therapy

Novel potent O-GlcNAcase (OGA) inhibitor (IC 50 : 46 nM), increasing the level of O-GlcNAcylated protein in cells and displaying suitable pharmacokinetic properties and brain permeability

Cell-permeable, fluorescent Ca2+ indicator

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist

Potent non-prostanoid inhibitor of platelet aggregation, acting via the prostacyclin receptor

Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI)

Blue fluorescent labeling reagent

Novel potent antileishmanial and antitrypanosomal agent, offering a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong in vivo efficacy in a visceral leishmaniasis mouse model (97%

Inhibitor of mitochondrial Lon protease and activator of DNA damage checkpoints

Potent agonist of the human 5-HT2A and 5-HT2C receptors

Novel Selective and Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase (hAMCase)

Poly(ADP-Ribose) Glycohydrolase (PARG) inhibitor

Novel GPR18 antagonist, blocking the effects of Abn-CBD and NAGly.

Novel inhibitor of advanced stages of breast cancer, targeting multiple cannabinoid anti-tumour pathways

Potent CB1 receptor antagonist